首页_上海市新药设计重点实验室
中文版 | 英文版

您当前位置:首页 > 人才队伍 > 固定人员

姓 名:陈卓
职 称:副研究员
电 话:/
传 真:/
email :/

人物详情

受教育经历:

2003/09 – 2010/06 华东理工大学,药学院药物化学专业,博士

1999/09 – 2010/06 华东理工大学,化学与制药学院制药工程专业, 学士

研究工作经历:

2015/09 – 至今  美国密西根大学,访问学者

2012/11 – 至今  华东理工大学,药学院上海市新药设计重点实验室,副研究员

2010/07 – 2012/10  中国科学院上海药物研究所,肿瘤药理研究室,博士后

研究方向:

1. 设计、合成小分子抗肿瘤化合物;

2. 探索抗肿瘤药物的作用机理;

3. 研究生物活性小分子的探针。

主要论著

[1] Yi Xiao,* Fengyu Liu, Zhuo Chen, Weipin Zhu, Yufang Xu and Xuhong Qian*. Discovery of a novel family of polycyclic aromatic molecules with unique reactivity and members valuable for fluorescent sensing and medicinal chemistry. Chemical Communication, 2015, 51, 6480-6488.

[2] Shaoying Tan, Kun Han, Qiang Li, Linjiang Tong, Yiqi Yang, Zhuo Chen*, Xie Hua*, Jian Ding, Xuhong Qian and Yufang Xu*. Novel metal complexes of naphthalimide-cyclam conjugates as potential multi-target receptor tyrosine kinase (RTK) inhibitors: Synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2014, 85, 207-214.

[3] Zhuo Chen, Xin Wang, Weiping Zhu, Xianwen Cao, Linjiang Tong, Honglin Li, Hua Xie,* Yufang Xu,* Shaoying Tan, Dong Kuang, Jian Ding, and Xuhong Qian*.  Acenaphtho[1,2-b]pyrrole-Based Selective Fibroblast Growth Factor Receptors 1 (FGFR1) Inhibitors: Design, Synthesis, and Biological Activity (vol 54, pg 3732, 2011). Journal of Medicinal Chemistry 2014, 57 (4), 1621-1624.

[4] Shaoying Tan, Hong Yin, Zhuo Chen*, Xuhong Qian, Yufang Xu*. Oxo-heterocyclic fused naphthalimides as antitumor agents: Synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2013, 62, 130-138.

[5] Zhuo Chen, Le Han, Minghao Xu, Yufang Xu*, Xuhong Qian*. Rationally designed multitarget anticancer agents. Current Medicinal Chemistry, 2013, 20, 1694-1714.

[6] Xin Wang, Zhuo Chen*, Linjiang Tong, Shaoying Tan, Wei Zhou, Ting Peng, Kun Han, Jian Ding, Hua Xie*, and Yufang Xu*. Naphthalimides Exhibit in vitro Antiproliferative and Antiangiogenic Activities by Inhibiting both Topoisomerase II (Topo II) and Receptor Tyrosine Kinases (RTKs). European Journal of Medicinal Chemistry, 2013, 65, 477-486

[7] Zhuo Chen, Xin Wang, Weiping Zhu, Xianwen Cao, Linjiang Tong, Honglin Li, Hua Xie*, Yufang Xu*, Shaoying Tan, Dong Kuang, Jian Ding, Xuhong Qian*, Acenaphtho [1,2-b]pyrrole Derivatives as Potent and Selective FGFR1 Inhibitors: Design, Synthesis and Biological Evaluation. Journal of Medicinal Chemistry, 2011, 54, 3732-3745.

[8] Bing Lin, Zhuo Chen, Yufang Xu, Huanying Zhang, Jianwen Liu*, Xuhong Qian, 7-b, a Novel Amonafide Analogue, Cause Growth Inhibition and Apoptosis in Raji Cells via a ROS-Mediated Mitochondrial Pathway. Leukemia Research, 2011, 35, 646-656.

[9] Hua Xie, Liping Lin, Linjiang Tong, Yong Jiang, Mingyue Zheng, Zhuo Chen, Xiaoyan Jiang, Xiaowei Zhang, Xiaowei Ren, Wenchao Qu, Yang Yang, Hua Wan, Yi Chen, Jianping Zuo, Hualiang Jiang, Meiyu Geng, Jian Ding*, AST1306, a Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo. PLoS ONE, 2011, 6(7): e21487

[10] Zhuo Chen, Xin Liang, Huanying Zhang, Hua Xie, Jianwen Liu, Yufang Xu*, Weiping Zhu, Yi Wang, Xin Wang, Shaoying Tan, Dong Kuang, Xuhong Qian*. A New Class of Naphthalimide-based Antitumor Agents that Inhibit Topoisomerase II (Topo II) and Induce Lysosomal Membrane Permeabilization (LMP) and Apoptosis. Journal of Medicinal Chemistry, 2010, 53, 2589-2600.

[11] 钱旭红,徐玉芳,陈 卓,朱维平,王 新,谭绍英,旷 东,谢 华;中国专利,8-氧-8H-苊并[1,2-b]吡咯衍生物,申请号:200910056554.2,公开号:CN101633637。

[12] 徐玉芳,陈 卓,钱旭红,朱维平,王 新,谭绍英,旷 东,刘建文,梁 欣;中国专利,  萘酰亚胺衍生物,申请号:200910056555.7,公开号:CN101633640。

[13] 钱旭红,朱维平,徐玉芳,张佩琢,徐晓勇,肖 义,陈 卓,段春晓;中国专利,一种荧光标记试剂,申请号:200510030078.9,公开号:CN1940563。

[14] 钱旭红,刘燕,徐玉芳,李君辉,孔祥明,陈卓,肖义,张元兴;中国专利,萘类衍生物及其在乏氧体系中的应用,申请号:CN200410017346.9,公开号:CN1563005。

参加项目:

[1] 国家自然科学基金(21302054),靶向Flt-3 的新型小分子抑制剂设计、合成及抗肿瘤活性研究,2014.1-2016.12,25万,主持人

the National Natural Science Foundation of China(grants 21302054)

[2] 上海市自然科学基金(13ZR1453100),靶向FLT3的新型小分子抑制剂研究, 2013.10.1-2016.9.30,10万,主持人

the Shanghai Committee of Science and Technology (grant 13ZR1453100),

[3]中央高校基本科研业务费探索研究基金,靶向FLT-3的新型小分子抑制剂研究,2013.6-2015.5,15万,主持人

the Fundamental Research Funds for the Central Universities

[4] 国家自然科学基金(81173080), 靶向FGFR1 的新型小分子抑制剂C11 抗肿瘤作用及其机制,2012.01-2015.12,50万,主要完成人

the National Natural Science Foundation of China(grants 81173080)

[5] 上海市化学生物学重点实验室开放基金(SKLCB-2012-05),靶向拓扑异构酶和组蛋白去乙酰化酶的新型多靶点抗肿瘤剂,2012.09.25—2013.08.31,1万,主持人the Opening Fund of Shanghai Key Laboratory of Chemical Biology (grant SKLCB-2012-05)


首页_上海市新药设计重点实验室